Cargando…

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma

Tumor mutational burden (TMB) is an emerging predictive marker of response to immune checkpoint inhibitor therapies. We evaluated the correlation between clinical indicators and high‐throughput sequencing results and TMB in lung adenocarcinoma patients, with the aim of finding simpler and more econo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Kai, Huang, Fengxiang, Wang, Yin, Kang, Yan, Wang, Qilong, Tang, Jiaqi, Sun, Panfeng, Lou, Jiaojiao, Qiao, Ruiping, Si, Jiming, Cao, Jian, Miao, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678101/ https://www.ncbi.nlm.nih.gov/pubmed/35521981 http://dx.doi.org/10.1002/cam4.4781

Ejemplares similares

Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report
por: Huang, Fengxiang, et al.
Publicado: (2022)

Pathogenesis of sarcopenia in chronic obstructive pulmonary disease
por: Ma, Kai, et al.
Publicado: (2022)

Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas
por: Wang, Changzheng, et al.
Publicado: (2019)

Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma
por: Ouyang, Rong, et al.
Publicado: (2021)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2021)

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
por: Wang, Xiaoxiao, et al.
Publicado: (2019)

Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer
por: Zhang, Fengxiang, et al.
Publicado: (2022)

miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma
por: Xue, Weijie, et al.
Publicado: (2021)

USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma
por: Sun, Yuanyuan, et al.
Publicado: (2021)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer
por: Hao, Shuai, et al.
Publicado: (2022)

340 "Sepan cuantos-- ", 1959-1979.
Publicado: (1979)

Health Tract No. 340: Non Sequitur
Publicado: (1868)

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma
por: Liu, Tingting, et al.
Publicado: (2022)

Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning
por: Niu, Yi, et al.
Publicado: (2022)

Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
por: Davidsson, Elsa, et al.
Publicado: (2017)

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation
por: Fu, Jing, et al.
Publicado: (2021)

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
por: Sung, Ji-Youn, et al.
Publicado: (2022)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

miR-340 suppresses glioblastoma multiforme
por: Huang, Daquan, et al.
Publicado: (2015)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
por: Jia, Mingming, et al.
Publicado: (2020)

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis
por: Yoneshima, Yasuto, et al.
Publicado: (2021)

Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program
por: Dickson, Sean, et al.
Publicado: (2023)

Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis
por: Wang, Yang, et al.
Publicado: (2022)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma
por: Cai, Haiqing, et al.
Publicado: (2014)

Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
por: Gao, Jing, et al.
Publicado: (2021)

Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients
por: Huang, Yili, et al.
Publicado: (2022)

Germline MC1R status influences somatic mutation burden in melanoma
por: Robles-Espinoza, Carla Daniela, et al.
Publicado: (2016)

Significance of thyroid transcription factor 1 and Napsin A for prompting the status of EGFR mutations in lung adenocarcinoma patients
por: Ren, Xiaolu, et al.
Publicado: (2022)

Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma
por: Fu, Min, et al.
Publicado: (2022)

S340 Emerging viral diseases: fighting an uphill battle
por: Lam, S.K.
Publicado: (2007)

Combination Effect of Engineered Endolysin EC340 With Antibiotics
por: Hong, Hye-Won, et al.
Publicado: (2022)

The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion
por: Du, Yun, et al.
Publicado: (2020)

Contributions of the Intrinsic Mutation Process to Cancer Mutation and Risk Burdens
por: Zhu, Wei, et al.
Publicado: (2017)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Combined ARHGEF6 and Tumor Mutational Burden may serve as a potential biomarker for immunotherapy of lung adenocarcinoma
por: Tong, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b4854jtjgveha8vp4c4991oe32